Comment
Author: Admin | 2025-04-28
File: Study Report A161C-US-21-C02, Zoetis Inc., 2022 3ZMR: GAH-284 Pets Since Launch September 2023 Data 4Data on File, APOQUEL/CYTOPOINT Pet Owner Tracker Wave 11, 2022, Zoetis Inc. 5Data on File, APOQUEL/CYTOPOINT Vet Tracker Wave 17, 2022, Zoetis Inc. 6PetTrak Total Unique Patient Count, December 2022, Zoetis Inc. 7Gonzales AJ, Bowman JW, Fici GJ, et al. Oclacitinib (APOQUEL)is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Therap. 2014;37(4)317-24. doi:10.1111/jvp.12101 8Gadeyne C, Little P, King VL, Edwards N, Davis K, Stegemann MR. Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Vet Dermatol. 2014;25(6):512-518,e86. doi:10.1111/vde.12166 9Cosgrove SB, Cleaver DM, King VL, et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet Dermatol. 2015;26(3):171-179, e35. doi: 10.1111/vde.12194 10Data on file. A Five-Year Post-Approval Safety Review for Apoquel® in the US (May 2013 to August 2018), Zoetis Inc.
Add Comment